{"nct_id":"NCT06380751","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2024-08-01","start_date_type":"ACTUAL","primary_completion_date":"2029-03-30","primary_completion_date_type":"ESTIMATED","completion_date":"2030-10-18","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}